Uncontrolled dyslipidemia, specifically elevation of low density lipoprotein cholesterol, is a major risk factor for developing cardiovascular disease. Currently, statin therapy remains first line treatment for reducing both serum cholesterol levels and cardiovascular risk. However, certain patients are unable to achieve desired serum cholesterol levels despite maximally tolerated statin therapy. As a result, several non-statin therapy avenues have been evaluated for their potential benefits in reducing cholesterol and cardiovascular risk. Bempedoic acid is one such non-statin therapy option which has been explored over the past few years to potentially assist patients in further reducing serum cholesterol. Bempedoic acid is a novel prodrug that inhibits cholesterol synthesis upstream of statins by inhibiting adenosine triphosphate-citrate lyase. Bempedoic acid has been studied as a single, once daily 180 mg dose. Administered as monotherapy or in combination with statin or ezetimibe, bempedoic acid significantly reduces low density lipoprotein cholesterol. Furthermore, bempedoic acid was generally well tolerated by patients and rates of adverse events were similar to placebo with few exceptions. Despite proven reductions in cholesterol and favorable safety profile, bempedoic acid will likely remain a third- or fourth-line agent for the treatment of dyslipidemia behind other non-statin therapies until improvement of cardiovascular outcomes is demonstrated in future clinical trials.

中文翻译：

---

Bempedoic Acid：治疗血脂异常的新途径。

不受控制的血脂异常，特别是低密度脂蛋白胆固醇升高，是发生心血管疾病的主要危险因素。目前，他汀类药物治疗仍然是降低血清胆固醇水平和心血管风险的一线治疗方法。然而，尽管进行了最大程度耐受的他汀类药物治疗，某些患者仍无法达到所需的血清胆固醇水平。因此，已经评估了几种非他汀类药物治疗途径在降低胆固醇和心血管风险方面的潜在益处。Bempedoic Acid 是一种非他汀类药物治疗选择，在过去几年中一直在探索，以潜在地帮助患者进一步降低血清胆固醇。Bempedoic Acid 是一种新型前药，通过抑制三磷酸腺苷-柠檬酸裂解酶来抑制他汀类药物上游的胆固醇合成。Bempedoic Acid 已被研究为每日一次 180 毫克的单一剂量。作为单一疗法或与他汀类药物或依折麦布联合使用，bempedoic 酸可显着降低低密度脂蛋白胆固醇。此外，bempedoic 酸通常被患者耐受良好，不良事件发生率与安慰剂相似，只有少数例外。尽管已证明可以降低胆固醇且安全性良好，但 bempedoic 酸可能仍然是其他非他汀类药物之后治疗血脂异常的三线或四线药物，直到在未来的临床试验中证明心血管结果得到改善。